CD274 and hepatocellular carcinoma: Herein, the purpose of the CHANCE001 study was to describe the efficacy and safety in a nationwide, retrospective, propensity score matching (PSM) cohort of HCC patients who received TACE with PD-(L)1 inhibitors plus MTT versus TACE monotherapy in the real-world setting.